Development DNA Recombinant DNA Technology Research 
Pharmaceutical Technology
FEBRUARY 24, 2023
Amivantamab is under clinical development by Johnson & Johnson and currently in Phase I for Colorectal Cancer. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It is based on DuoBody technology platform.
Roots Analysis
JANUARY 21, 2024
With fourteen approved drugs and several drug candidates being evaluated under different stages of development, antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics. Over time, a variety of other conjugated therapeutics have also been developed and are under evaluation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
DECEMBER 29, 2022
Recombinant DNA technology and its impact on modern drug discovery . Exploring the microbiome: how it is shaping preclinical research . Mini-library approach delivers an arsenal in drug development pipeline . Catch up on the Sitting Down With podcast episodes released in 2022: . Narrated Podcasts.
Cloudbyz
MARCH 6, 2024
Unlike traditional small molecule drugs, which are chemically synthesized, biologics are produced through complex biotechnological processes, often involving recombinant DNA technology. Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins.
Pharmaceutical Technology
FEBRUARY 15, 2023
110 innovations will shape the pharmaceutical industry According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
The Pharma Data
JULY 11, 2021
Hereditary angioedema is a lifelong condition and research shows that concerns about another attack can limit the way patients lead their lives,” said Prof. TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. percent (-100; 852.8), and the median reduction was 97.7 Markus Magerl, M.D.,
Drug Discovery World
MAY 4, 2023
The potential of drug targets Over the next 50 years, new targets emerged and drugs were developed against them. Recombinant DNA technology and improved protein purification techniques further contributed to our understanding and explorations of drug targets. Thus, there was a dire need for new and effective drug targets.
Expert insights. Personalized for you.
100 
Let's personalize your content